BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 33453094)

  • 21. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
    Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
    PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
    Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
    Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J; Ma CX
    Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CDK4/6 inhibitors in breast cancer - from
    Saleh L; Wilson C; Holen I
    Acta Oncol; 2020 Feb; 59(2):219-232. PubMed ID: 31671026
    [No Abstract]   [Full Text] [Related]  

  • 27. Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
    Iida M; Toyosawa D; Nakamura M; Tsuboi K; Tokuda E; Niwa T; Ishida T; Hayashi SI
    Breast Cancer; 2020 Sep; 27(5):963-972. PubMed ID: 32297248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Fang H; Huang D; Yang F; Guan X
    Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
    Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
    Rossi L; McCartney A; Risi E; De Santo I; Migliaccio I; Malorni L; Biganzoli L; Di Leo A
    Clin Breast Cancer; 2019 Dec; 19(6):392-398. PubMed ID: 31358432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?
    Shah M; Nunes MR; Stearns V
    Oncology (Williston Park); 2018 May; 32(5):216-22. PubMed ID: 29847850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials.
    Munzone E; Pagan E; Bagnardi V; Montagna E; Cancello G; Dellapasqua S; Iorfida M; Mazza M; Colleoni M
    ESMO Open; 2021 Dec; 6(6):100332. PubMed ID: 34864350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
    Agostinetto E; Debien V; Marta GN; Lambertini M; Piccart-Gebhart M; de Azambuja E
    Eur J Clin Invest; 2021 Jul; 51(7):e13535. PubMed ID: 33662161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
    Piezzo M; Cocco S; Caputo R; Cianniello D; Gioia GD; Lauro VD; Fusco G; Martinelli C; Nuzzo F; Pensabene M; De Laurentiis M
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer.
    Migliaccio I; Bonechi M; McCartney A; Guarducci C; Benelli M; Biganzoli L; Di Leo A; Malorni L
    Cancer Treat Rev; 2021 Feb; 93():102136. PubMed ID: 33360919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies.
    Cortés J; Im SA; Holgado E; Perez-Garcia JM; Schmid P; Chavez-MacGregor M
    Cancer Treat Rev; 2017 Dec; 61():53-60. PubMed ID: 29100169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer.
    Cruz M; Reinert T; Cristofanilli M
    Clin Pharmacol Ther; 2018 Jun; 103(6):1009-1019. PubMed ID: 29226311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.